pd-l1 antibody
PD-L1 Antibody |
|||
4059-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4). |
|||
PD-L1 Antibody |
|||
4059-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4). |
|||
PD-L1 Antibody |
|||
P1013-01m | SAB | 0.1m | 224.4 EUR |
PD-L1 Antibody |
|||
P1013-1ml | SAB | 1ml | 807.6 EUR |
PD-L1 Antibody |
|||
R31573 | NSJ Bioreagents | 100 ug | 419 EUR |
PD-L1 Antibody |
|||
R33263-100UG | NSJ Bioreagents | 100 ug | 399 EUR |
Anti-PD-L1 Antibody |
|||
A1454-100 | Biovision | 405.6 EUR | |
Anti-PD-L1 Antibody |
|||
A1454-30T | Biovision | 175.2 EUR | |
Mouse PD-L1 Antibody |
|||
32903-05111 | AssayPro | 150 ug | 313.2 EUR |
PD-L1 Conjugated Antibody |
|||
C49251 | SAB | 100ul | 476.4 EUR |
PD-L1 Antibody [F6A9] |
|||
SD8639-002mg | ProSci | 0.02 mg | 253.22 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
|||
PD-L1 Antibody [F6A9] |
|||
SD8639-01mg | ProSci | 0.1 mg | 723.62 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
|||
PD-L1 Antibody [F2G2] |
|||
SD8641-002mg | ProSci | 0.02 mg | 253.22 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
|||
PD-L1 Antibody [F2G2] |
|||
SD8641-01mg | ProSci | 0.1 mg | 723.62 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
|||
Anti-PD-L1 antibody |
|||
STJ130022 | St John's Laboratory | 50 µl | 385.2 EUR |
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
|||
Anti-PD-L1 antibody |
|||
STJ130023 | St John's Laboratory | 50 µl | 385.2 EUR |
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
|||
Anti-PD-L1 antibody |
|||
STJ130024 | St John's Laboratory | 50 µl | 385.2 EUR |
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
|||
Anti-PD-L1 antibody |
|||
STJ180217 | St John's Laboratory | 0.1 ml | 336 EUR |
Anti-PD-L1 antibody |
|||
STJ180383 | St John's Laboratory | 0.1 ml | 295.2 EUR |
Anti-PD-L1 antibody |
|||
STJ190082 | St John's Laboratory | 200 µl | 236.4 EUR |
Description: Unconjugated Mouse monoclonal to PD-L1 (AS1A7) |
|||
PD-L1 Peptide |
|||
46-156P | ProSci | 0.1 mg | 405.6 EUR |
Description: CD274 / PD-L1 Peptide |
|||
PD-L1 Peptide |
|||
4059P | ProSci | 0.05 mg | 197.7 EUR |
Description: (IN) PD-L1 peptide |
|||
PD-L1 Protein |
|||
20-abx263458 | Abbexa |
|
|
PD-L1 Protein |
|||
20-abx261703 | Abbexa |
|
|
Anti-PD-L1 |
|||
DB-241-0.1 | DB Biotech | 100 μl | 469.2 EUR |
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated |
|||
Anti-PD-L1 |
|||
DB-241-0.2 | DB Biotech | 200 μl | 675.6 EUR |
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated |
|||
Anti-PD-L1 |
|||
DB-241-0.5 | DB Biotech | 500 μl | 889.2 EUR |
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated |
|||
Anti-PD-L1 |
|||
DB-241-1 | DB Biotech | 1 ml | 1450.8 EUR |
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated |
|||
Anti-PD-L1 |
|||
DB-241-RTU-15 | DB Biotech | 15 ml | 813.6 EUR |
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use) |
|||
Anti-PD-L1 |
|||
DB-241-RTU-7 | DB Biotech | 7 ml | 519.6 EUR |
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use) |
|||
Anti-PD-L1 |
|||
DB241-RTU-15 | DB Biotech | 15 ml | 813.6 EUR |
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use) |
|||
Anti-PD-L1 |
|||
DB241-RTU-7 | DB Biotech | 7 ml | 519.6 EUR |
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use) |
|||
PD-L1, CD274 |
|||
E6TA00108 | EnoGene | 0.1mg | 411.6 EUR |
PD-1/PD-L1 inhibitor 2 |
|||
B6023-25 | ApexBio | 25 mg | 525.6 EUR |
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor. |
|||
PD-1/PD-L1 inhibitor 2 |
|||
B6023-5 | ApexBio | 5 mg | 205.2 EUR |
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor. |
|||
PD-1/PD-L1 inhibitor 1 |
|||
B6172-25 | ApexBio | 25 mg | 543.6 EUR |
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
|||
PD-1/PD-L1 inhibitor 1 |
|||
B6172-5 | ApexBio | 5 mg | 201.6 EUR |
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
|||
PD-1/PD-L1 Inhibitor 2 |
|||
B1050-25 | Biovision | 679.2 EUR | |
PD-1/PD-L1 Inhibitor 2 |
|||
B1050-5 | Biovision | 242.4 EUR | |
PD-1/PD-L1 Inhibitor 1 |
|||
B1213-25 | Biovision | 679.2 EUR | |
Anti-PD-L1 Antibody (IHC411) |
|||
A1549-50 | Biovision | 222 EUR | |
Anti-PD-L1/CD274 antibody |
|||
PAab06280 | Lifescience Market | 100 ug | 426 EUR |
anti- PD-L1/CD274 antibody |
|||
FNab06280 | FN Test | 100µg | 606.3 EUR |
Description: Antibody raised against PD-L1/CD274 |
|||
anti- PD-L1/CD274 antibody |
|||
FNab06281 | FN Test | 100µg | 658.5 EUR |
Description: Antibody raised against PD-L1/CD274 |
|||
Anti-PD-L1/CD274 Antibody |
|||
PA1851 | BosterBio | 100ug/vial | 352.8 EUR |
Anti-PD-L1/CD274 Antibody |
|||
PB9154 | BosterBio | 100ug/vial | 352.8 EUR |
Anti-PD-L1/CD274 Antibody |
|||
PB9994 | BosterBio | 100ug/vial | 352.8 EUR |
Anti-CD274 / PD-L1 antibody |
|||
STJ70646 | St John's Laboratory | 100 µg | 430.8 EUR |
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody |
|||
20-abx319445 | Abbexa |
|
|
Ribosome-inactivating protein PD-L1/PD-L2 Antibody |
|||
1-CSB-PA306294LA01PJJ | Cusabio |
|
|
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA |
|||
PD-L1 Rabbit pAb |
|||
A11273-100ul | Abclonal | 100 ul | 369.6 EUR |
PD-L1 Rabbit pAb |
|||
A11273-200ul | Abclonal | 200 ul | 550.8 EUR |
PD-L1 Rabbit pAb |
|||
A11273-20ul | Abclonal | 20 ul | 219.6 EUR |
PD-L1 Rabbit pAb |
|||
A11273-50ul | Abclonal | 50 ul | 267.6 EUR |
PD-L1 Recombinant Protein |
|||
91-293 | ProSci | 0.05 mg | 405.6 EUR |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. |